Fmr LLC Sells 428,768 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC)

FMR LLC cut its holdings in shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) by 14.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,521,511 shares of the company's stock after selling 428,768 shares during the quarter. FMR LLC owned about 2.97% of Century Therapeutics worth $4,312,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Century Therapeutics during the third quarter worth approximately $27,000. Rhumbline Advisers increased its position in shares of Century Therapeutics by 56.0% during the second quarter. Rhumbline Advisers now owns 52,466 shares of the company's stock valued at $134,000 after purchasing an additional 18,828 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Century Therapeutics by 141.7% during the second quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company's stock valued at $192,000 after purchasing an additional 44,155 shares during the period. Bank of New York Mellon Corp increased its position in shares of Century Therapeutics by 110.1% during the second quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company's stock valued at $380,000 after purchasing an additional 78,088 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Century Therapeutics by 6.1% during the second quarter. Renaissance Technologies LLC now owns 165,500 shares of the company's stock valued at $422,000 after purchasing an additional 9,500 shares during the period. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Stock Performance

NASDAQ:IPSC traded down $0.03 during mid-day trading on Friday, hitting $1.22. 953,106 shares of the stock were exchanged, compared to its average volume of 306,248. Century Therapeutics, Inc. has a fifty-two week low of $1.14 and a fifty-two week high of $5.51. The firm's 50-day simple moving average is $1.41 and its 200 day simple moving average is $1.92. The stock has a market capitalization of $103.74 million, a price-to-earnings ratio of -0.66 and a beta of 1.65.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The company had revenue of $0.79 million during the quarter, compared to analysts' expectations of $0.47 million. During the same quarter in the prior year, the firm posted ($0.55) earnings per share. On average, analysts predict that Century Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on IPSC. Chardan Capital reduced their price objective on Century Therapeutics from $17.00 to $11.00 and set a "buy" rating on the stock in a research note on Thursday, November 7th. HC Wainwright cut their price target on Century Therapeutics from $9.00 to $5.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $11.60.

Century Therapeutics Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.